Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nanogen, a developer of diagnostic products, has been granted US patent no. RE39,816, which is a reissue of US patent no. 6,461,828, titled, ‘Conjunctive Analysis of Biological Marker Expression For Predicting Cardiac Mortality’.
Subscribe to our email newsletter
The patent relates to the combined use of a cardiac marker of cell injury, such as Troponin I, with a marker of organ adaptation, such as brain natriuretic peptide (BNP), for prognosis of chronic congestive heart failure (CHF) patients. The new claims strengthen the company’s intellectual property rights around the combined use of these two types of important biomarkers.
Howard Birndorf, CEO of Nanogen, said: “The combined use of Troponin I and BNP to evaluate the progress of congestive heart failure is just one example of how physicians currently combine biomarkers in cardiac care.”